Press Releases.

Month Year

Month Year

Investor Alerts

January 21, 2016

Regulus Completes RG-101 Enrollment in Phase II Combination Study

- Additional studies on track for enrollment in H12016 with multiple data read-outs expected throughout 2016 -
- Photos 1
January 06, 2016

Regulus Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- Photos 1
December 18, 2015

RG-125(AZD4076), a microRNA Therapeutic Targeting microRNA-103/107 Being Developed for the Treatment of NASH in Patients with Type 2 Diabetes/Pre-Diabetes, Enters Phase I Clinical Development

-Regulus Earns $10.0 Million Milestone Payment from AstraZeneca and Achieves Key Goal for 2015-
- Photos 1
December 07, 2015

Regulus Appoints Joseph P. Hagan Chief Operating Officer
- Photos 1
November 12, 2015

Regulus Announces Grant of Patents Covering Lead microRNA Therapeutics
- Photos 1

Show per page